The endometrial cancer market is expected to grow at USD 30.18 billion in 2025 and is estimated to grow from USD 31.85 billion in 2026 to reach USD 40.71 billion by 2031, at a CAGR of 5.03% during the forecast period (2026-2031). This report is segmented by Offering (Therapeutics, Services), Type of Cancer (Endometrioid Adenocarcinoma, Carcinosarcoma, and More), Care Delivery Setting (Hospitals, Cancer Treatment Centers, Specialty Oncology / Gynecology Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Therapeutics is projected to grow at a 6.59% CAGR through 2031, above the overall endometrial cancer market growth rate. Immunotherapy now has a larger role in advanced disease following the 2024 approvals of pembrolizumab, durvalumab, and dostarlimab combinations. Chemotherapy remains part of the treatment backbone because carboplatin and paclitaxel are used with the approved checkpoint inhibitors. Targeted therapy is gaining relevance for molecularly defined tumors and for patients with recurrent disease. The therapeutics segment, therefore, concentrates much of the endometrial cancer market’s future value growth.
Europe is a major treatment region, led by Germany, France, the United Kingdom, Italy, and Spain. The 2025 ESGO-ESTRO-ESP update integrated the revised FIGO molecular staging framework into clinical management, supporting more tailored adjuvant treatment and molecular classification. European Medicines Agency approvals do not ensure immediate national reimbursement. The French assessment for dostarlimab reported an incremental cost-effectiveness ratio of EUR 150,697 per quality-adjusted life-year, equivalent to USD 165,000, and a 3-year budget impact of EUR 429 million, equivalent to USD 471 million. Eastern European markets face greater infrastructure and pricing constraints, which lengthen adoption timelines.
Asia-Pacific is projected to grow at a 5.90% CAGR through 2031, the fastest regional rate in the endometrial cancer market. Japan approved pembrolizumab with chemotherapy in December 2024, while AstraZeneca Japan received approval for Imfinzi and Lynparza in November 2024. South Korea has approvals in place, but reimbursement remains a key barrier, while China’s domestic oncology manufacturing base and real-world evidence pathway can support faster regulatory activity. The high modeled cost-effectiveness ratio for pembrolizumab in mismatch repair proficient disease creates pressure for price negotiations, and the Middle East, Africa, and South America remain price-sensitive opportunities with longer access cycles.
Global Endometrial Cancer Market Trends and Insights
Rising Prevalence Linked to Obesity and Aging Women
The endometrial cancer market is supported by risk factors that are not likely to reverse quickly. Historical U.S. incidence data show an upward pattern, and excess estrogen produced by adipose tissue is a key biological link between obesity and disease risk. The Lancet projected that total global cancer incidence will reach 30.5 million cases by 2050, 60.7% higher than in 2024. Endometrial cancer is concentrated among postmenopausal women aged 60 to 74, making aging populations especially relevant to care demand. Evidence also indicates rising incidence among younger women. Younger patients may have different insurance coverage and treatment uptake than older populations, which broadens demand across the endometrial cancer market.Rapid Adoption of Immunotherapy-Chemotherapy Combinations
The endometrial cancer market is being reshaped by a rapid change in first-line treatment for advanced and recurrent disease. Merck received U.S. approval in June 2024 for pembrolizumab with carboplatin and paclitaxel for adult patients with primary advanced or recurrent endometrial carcinoma, regardless of mismatch repair status. A 2026 meta-analysis of 10 randomized trials involving 4,052 patients found median progression-free survival of 14.6 months with PD-1 or PD-L1 inhibitors plus chemotherapy, compared with 10.2 months with chemotherapy alone. It also reported median overall survival of 43.7 months compared with 29.1 months, raising the clinical standard for later entrants in the endometrial cancer market.High Treatment Costs of Novel Agents
High prices can limit the endometrial cancer market even when clinical evidence is strong. A 2025 cost-effectiveness analysis found an incremental cost-effectiveness ratio of USD 220,259 per quality-adjusted life-year for pembrolizumab plus chemotherapy in mismatch repair proficient patients in China. The same analysis reported USD 70,207 per quality-adjusted life-year in mismatch repair-deficient patients. A separate 2025 analysis found that durvalumab pricing would need a 90% reduction to meet its modeled cost-effectiveness threshold for mismatch repair-deficient disease in the United States. In France, the Haute Autorité de Santé estimated a 3-year budget impact of EUR 429 million, equivalent to USD 471 million, for dostarlimab in an estimated 14,540 patients. These findings show why price negotiations and reimbursement rules can delay adoption in the endometrial cancer market.Other drivers and restraints analyzed in the detailed report include:
- Favorable Reimbursement for Targeted Therapies
- Growth in Minimally Invasive Diagnostic Procedures
- Drug-Related Toxicities Limiting Adherence
Segment Analysis
Services held 73.77% of the market share in 2025 because most patients need diagnosis, surgery, radiation, and follow-up before systemic therapy. Diagnostic services include biopsy, pelvic and transvaginal ultrasound, hysteroscopy, and computed tomography. These services establish disease presence, stage, and treatment planning. Surgical services remain essential because hysterectomy is central to the care of many patients with localized disease. Radiotherapy services provide adjuvant care and management for selected recurrent cases. The service mix remains broad because the disease pathway spans screening, diagnosis, treatment, and surveillance.Therapeutics is projected to grow at a 6.59% CAGR through 2031, above the overall endometrial cancer market growth rate. Immunotherapy now has a larger role in advanced disease following the 2024 approvals of pembrolizumab, durvalumab, and dostarlimab combinations. Chemotherapy remains part of the treatment backbone because carboplatin and paclitaxel are used with the approved checkpoint inhibitors. Targeted therapy is gaining relevance for molecularly defined tumors and for patients with recurrent disease. The therapeutics segment, therefore, concentrates much of the endometrial cancer market’s future value growth.
Complete Report Scope:
- By Offering
- Therapeutics
- Immunotherapy
- Chemotherapy
- Targeted Therapy
- Hormonal Therapy
- Other Therapeutics
- Services
- Diagnostic Services
- Biopsy
- Pelvic / Transvaginal Ultrasound
- Hysteroscopy
- CT Scan
- Radiotherapy Services
- Surgical Services
- Other Services
- Diagnostic Services
- Therapeutics
- By Type of Cancer
- Endometrioid Adenocarcinoma
- Carcinosarcoma
- Squamous Cell Carcinoma
- Others
- By Care Delivery Setting
- Hospitals
- Cancer Treatment Centers
- Specialty Oncology / Gynecology Clinics
- Diagnostic Laboratories
- Ambulatory Surgical Centers
- Others
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 41.29% of the market share in 2025 and remains the largest regional contributor. The region benefits from dense oncology infrastructure, established reimbursement systems, and broad availability of approved immunotherapies. The United States has a high disease burden associated with obesity, and the American Cancer Society reported mortality rates of 9.0 per 100,000 among Black women and 4.6 per 100,000 among White women. Canada and Mexico add demand through their public and private oncology systems. The endometrial cancer market in North America remains shaped by differences in insurance coverage, specialist access, and molecular testing.Europe is a major treatment region, led by Germany, France, the United Kingdom, Italy, and Spain. The 2025 ESGO-ESTRO-ESP update integrated the revised FIGO molecular staging framework into clinical management, supporting more tailored adjuvant treatment and molecular classification. European Medicines Agency approvals do not ensure immediate national reimbursement. The French assessment for dostarlimab reported an incremental cost-effectiveness ratio of EUR 150,697 per quality-adjusted life-year, equivalent to USD 165,000, and a 3-year budget impact of EUR 429 million, equivalent to USD 471 million. Eastern European markets face greater infrastructure and pricing constraints, which lengthen adoption timelines.
Asia-Pacific is projected to grow at a 5.90% CAGR through 2031, the fastest regional rate in the endometrial cancer market. Japan approved pembrolizumab with chemotherapy in December 2024, while AstraZeneca Japan received approval for Imfinzi and Lynparza in November 2024. South Korea has approvals in place, but reimbursement remains a key barrier, while China’s domestic oncology manufacturing base and real-world evidence pathway can support faster regulatory activity. The high modeled cost-effectiveness ratio for pembrolizumab in mismatch repair proficient disease creates pressure for price negotiations, and the Middle East, Africa, and South America remain price-sensitive opportunities with longer access cycles.
List of Companies Covered in this Report:
- AstraZeneca
- BioNTech
- Context Therapeutics Inc.
- Doma Biopharmaceutical (Suzhou) Co., Ltd
- Eisai
- GlaxoSmithKline
- Karyopharm Therapeutics
- Merck
- Pfizer
- TORL BioTherapeutics LLC
- City of Hope
- Dana-Farber Cancer Institute, Inc.
- Fresenius
- HCA Healthcare, Inc.
- IHH Healthcare Berhad
- Mayo Foundation for Medical Education and Research (MFMER)
- Memorial Sloan Kettering Cancer Center
- Minnesota Oncology
- Northwestern Medicine
- The University of Texas MD Anderson Cancer Center
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca
- BioNTech SE
- Context Therapeutics Inc.
- Doma Biopharmaceutical (Suzhou) Co., Ltd
- Eisai Co., Ltd
- GSK plc
- Karyopharm Therapeutics, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- TORL BioTherapeutics LLC
- City of Hope
- Dana-Farber Cancer Institute, Inc.
- Fresenius SE & Co. KGaA
- HCA Healthcare, Inc.
- IHH Healthcare Berhad
- Mayo Foundation for Medical Education and Research (MFMER)
- Memorial Sloan Kettering Cancer Center
- Minnesota Oncology
- Northwestern Medicine
- The University of Texas MD Anderson Cancer Center
